NuVasive Stock Forecast, Price & News

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for NuVasive in the last year. There are currently 1 sell rating, 5 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" NuVasive stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in NUVA, but not buy additional shares or sell existing shares.
View analyst ratings for NuVasive or view top-rated stocks.

Wall Street analysts have given NuVasive a "Hold" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but NuVasive wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

NuVasive is scheduled to release its next quarterly earnings announcement on Wednesday, July 28th 2021.
View our earnings forecast for NuVasive.

NuVasive will be holding an earnings conference call on Wednesday, July 28th at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link or dial in at 412-317-6671 with passcode "13720558".

NuVasive, Inc. (NASDAQ:NUVA) posted its quarterly earnings results on Wednesday, May, 5th. The medical device company reported $0.37 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.35 by $0.02. The medical device company earned $271.25 million during the quarter, compared to analysts' expectations of $261.12 million. NuVasive had a negative net margin of 4.70% and a positive trailing twelve-month return on equity of 6.47%.
View NuVasive's earnings history.

NuVasive's stock was trading at $49.41 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, NUVA shares have increased by 33.0% and is now trading at $65.73.
View which stocks have been most impacted by COVID-19.

11 Wall Street analysts have issued 12-month price objectives for NuVasive's stock. Their forecasts range from $48.00 to $80.00. On average, they expect NuVasive's stock price to reach $67.18 in the next twelve months. This suggests a possible upside of 2.2% from the stock's current price.
View analysts' price targets for NuVasive or view top-rated stocks among Wall Street analysts.

59 employees have rated NuVasive CEO Chris Barry on Glassdoor.com. Chris Barry has an approval rating of 88% among NuVasive's employees.

Some companies that are related to NuVasive include Abbott Laboratories (ABT), Medtronic (MDT), Intuitive Surgical (ISRG), Stryker (SYK), Becton, Dickinson and (BDX), Edwards Lifesciences (EW), Boston Scientific (BSX), IDEXX Laboratories (IDXX), DexCom (DXCM), Baxter International (BAX), ResMed (RMD), Teleflex (TFX), Hologic (HOLX), STERIS (STE) and Insulet (PODD).
View all of NUVA's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other NuVasive investors own include BioMarin Pharmaceutical (BMRN), Incyte (INCY), Puma Biotechnology (PBYI), Intel (INTC), Alibaba Group (BABA), (MDVN) (MDVN), Micron Technology (MU), Bank of America (BAC), Gilead Sciences (GILD) and Applied Materials (AMAT).

NuVasive trades on the NASDAQ under the ticker symbol "NUVA."

NuVasive's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Scout Investments Inc. (1.07%), Oregon Public Employees Retirement Fund (0.03%) and New Mexico Educational Retirement Board (0.02%). Company insiders that own NuVasive stock include Gregory T Lucier, James Christopher Barry, Lucas Vitale, Massimo Calafiore, Matthew Link and Paul Mcclintock.
View institutional ownership trends for NuVasive.

NUVA stock was sold by a variety of institutional investors in the last quarter, including Scout Investments Inc.. Company insiders that have sold NuVasive company stock in the last year include James Christopher Barry, Lucas Vitale, and Massimo Calafiore.
View insider buying and selling activity for NuVasive or view top insider-selling stocks.

NUVA stock was purchased by a variety of institutional investors in the last quarter, including New Mexico Educational Retirement Board, and Oregon Public Employees Retirement Fund.
View insider buying and selling activity for NuVasive or or view top insider-buying stocks.

Shares of NUVA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of NUVA stock can currently be purchased for approximately $65.73.

NuVasive has a market capitalization of $3.39 billion and generates $1.05 billion in revenue each year. The medical device company earns $-37,150,000.00 in net income (profit) each year or $1.23 on an earnings per share basis.

NuVasive employs 2,700 workers across the globe.

The following companies are subsidiares of NuVasive: Biotronic NeuroNetwork, Ellipse Technologies, and SafePassage.

NuVasive was founded in 1997.

The official website for NuVasive is www.nuvasive.com.

NuVasive is headquartered at 7475 LUSK BOULEVARD, SAN DIEGO CA, 92121.

NuVasive's mailing address is 7475 LUSK BOULEVARD, SAN DIEGO CA, 92121. The medical device company can be reached via phone at (858) 909-1800 or via email at [email protected]